Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 66

Sort by

Sort Order Select

Journal Articles

Impact of Total Body Irradiation-Based Conditioning Regimens on Outcomes in Patients with Aggressive Mature T-Cell Lymphomas Undergoing Allogeneic Hematopoietic Cell Transplant

Yenny Alejandra Moreno Vanegas, Urshila Durani, Christine Goth, Nandita Khera, Zhuo Li, Hemant S. Murthy, Vivek Roy, James M. Foran, Ernesto Ayala, Mohamed A. Kharfan-Dabaja, Jasmine Zain, Madiha Iqbal

Blood (2024) 144 (Supplement 1): 507.

https://doi.org/10.1182/blood-2024-206020

Published: 2024

Journal Articles

Response-Stratified Genetic Risk Model for Newly-Diagnosed Acute Myeloid Leukemia Treated with Venetoclax + Hypomethylating Agent

Blood (2024) 144 (Supplement 1): 4247.

https://doi.org/10.1182/blood-2024-204114

Published: 2024

Journal Articles

Predictors of Relapse and Post-Relapse Outcomes in Patients with Newly-Diagnosed Acute Myeloid Leukemia Treated with Venetoclax + Hypomethylating Agent

Blood (2024) 144 (Supplement 1): 2852.

https://doi.org/10.1182/blood-2024-209015

Published: 2024

Journal Articles

Revumenib Maintenance Therapy Following Revumenib-Induced Remission and Transplant

Andrius Zucenka, Ghayas C. Issa, Martha Arellano, Sajad Khazal, Nandita Khera, Wendy Stock, Branko Cuglievan, Yu Gu, Huy Van Nguyen, Angela R. Smith, Eytan M. Stein

Blood (2023) 142 (Supplement 1): 4950.

https://doi.org/10.1182/blood-2023-189036

Published: 2023

Journal Articles

Trial in Progress: Patient-Reported Outcome Measures in the Prospective Observational Cohort Study of Patients at Risk for Chronic Graft-Versus-Host Disease in the United States (THRIVE)

Doris M. Ponce, Areej El-Jawahri, Betty K. Hamilton, Nandita Khera, Valkal Bhatt, John Galvin, Catherine J. Lee

Blood (2023) 142 (Supplement 1): 7035.

https://doi.org/10.1182/blood-2023-178073

Published: 2023

Journal Articles

Preliminary Safety Results of the Open-Label Phase of a 2-Part Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of an Investigational Microbiome Therapeutic, SER-155, in Adults Undergoing Hematopoietic Cell Transplantation

Doris M. Ponce, Satyajit Kosuri, Nandita Khera, Zachariah Defilipp, David I Lichter, Jonathan U Peled, Marcel R.M. van den Brink, Kelly Brady, Matthew D Puhl, Gabrielle Glick, Brooke Hasson, Barbara H McGovern, Lisa von Moltke, Bina Tejura

Blood (2023) 142 (Supplement 1): 6994.

https://doi.org/10.1182/blood-2023-180119

Published: 2023

Journal Articles

Impact of Investigational Microbiome Therapeutic SER-155 on Pathogen Domination: Initial Results from a Phase 1b Study in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT)

Jonathan U. Peled, Marcel R.M. van den Brink, Doris M. Ponce, Satyajit Kosuri, Nandita Khera, Zachariah DeFilipp, Bina Tejura, David I Lichter, Mary-Jane Lombardo, Meghan Chafee, Jennifer R Wortman, Timothy Straub, Emily Walsh, Augustus Ge, David Lyttle, Brooke Hasson, Christopher Ford, Lisa von Moltke, Matthew Henn

Blood (2023) 142 (Supplement 1): 2198.

https://doi.org/10.1182/blood-2023-188885

Published: 2023

Journal Articles

Survival and Prognosis Among 301 Patients with Newly-Diagnosed Acute Myeloid Leukemia Following Venetoclax Plus Hypomethylating Agent Therapy

Blood (2023) 142 (Supplement 1): 591.

https://doi.org/10.1182/blood-2023-178837

Published: 2023

Journal Articles

Evaluation of Atrial Fibrillation Risk and Outcome after Allogeneic Transplantation Using an Artificial Intelligence ECG Algorithm and Echocardiographic Parameters in an MDS Cohort

Mario Ballerini, Michael Heckman, Launia White, Razan Mohty, Yenny Vanegas Moreno, Hassan Alkhateeb, Mohamed A. Kharfan-Dabaja, Nandita Khera, William J. Hogan, Mark R. Litzow, Abhishek A Mangaonkar, Hemant S. Murthy, Jeanne Palmer, Mithun V Shah, Lisa Sproat, Chris Ray, James M. Foran

Blood (2023) 142 (Supplement 1): 2287.

https://doi.org/10.1182/blood-2023-183019

Published: 2023

Journal Articles

Impact of Publicly Reported Center Specific Analysis on Patient Selection Practices for Hematopoietic Stem Cell Transplantation

Christopher Strouse, Mark Juckett, Brent R. Logan, Noel Estrada-Merly, Jaime M. Preussler, Tony Truong, Jesse Troy, Nandita Khera, William Wood, Hemalatha G. Rangarajan, Luke Akard, Neel S. Bhatt, Akshay Sharma, Wael Saber

Blood (2023) 142 (Supplement 1): 373.

https://doi.org/10.1182/blood-2023-182013

Published: 2023

Journal Articles

TP53 Variant Allele Frequency and Therapy-Related Setting Independently Predict Survival in Myelodysplastic Syndromes with Del(5q)

Blood (2023) 142 (Supplement 1): 3234.

https://doi.org/10.1182/blood-2023-185023

Published: 2023

Journal Articles

Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation for Hodgkin and Non-Hodgkin Lymphoma: Secondary Analysis from Two Multi-Center Randomized Controlled Trials of Hematopoietic Cell Transplant Survivorship Interventions

Blood (2022) 140 (Supplement 1): 8019–8021.

https://doi.org/10.1182/blood-2022-167411

Published: 2022

Journal Articles

IPSS-Molecular but Not Individual Mutations Predicts Outcomes of Patients with Myelodysplastic Syndrome (MDS) after Allogeneic Hematopoietic Cell Transplantation (Allo-HCT): A Mayo Clinic Cohort

Razan Mohty, Yenny Moreno Vanegas, Michael G. Heckman, Hassan B. Alkhateeb, Alexander P. Hochwald, William J. Hogan, Mohamed A. Kharfan-Dabaja, Rhett P. Ketterling, Nandita Khera, Mark R. Litzow, Abhishek A. Mangaonkar, Hemant S. Murthy, Jeanne M. Palmer, Mithun V. Shah, Lisa Z. Sproat, David S. Viswanatha, James M. Foran

Blood (2022) 140 (Supplement 1): 4863–4864.

https://doi.org/10.1182/blood-2022-168053

Published: 2022

Journal Articles

Outcomes after Transplant in Relapsed/Refractory KMT2Ar (MLLr) and mNPM1 (NPM1c) leukemia Patients Achieving Remissions after Menin Inhibition: SNDX-5613 (revumenib) Ph1 Experience

Blood (2022) 140 (Supplement 1): 914–916.

https://doi.org/10.1182/blood-2022-164600

Published: 2022

Journal Articles

A Phase 1b Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of an Investigational Microbiome Therapeutic, SER-155, in Adults Undergoing Hematopoietic Stem Cell Transplantation

Doris M Ponce, Jonathan U Peled, Bindu Tejura, Christopher Ford, Marcel R M van den Brink, Mary Jane Lombardo, Satyajit Kosuri, Nandita Khera, Zachariah Defilipp, Lisa von Moltke

Blood (2022) 140 (Supplement 1): 10532–10533.

https://doi.org/10.1182/blood-2022-162386

Published: 2022

Journal Articles

Reappraisal of Mast Cell Leukemia Based on a Single Institution Review of 16 Cases: Role of Mast Cell Morphology in Determining Clinical Outcome

Animesh Pardanani, Ayalew Tefferi, Amritpal Singh, Aref Al-Kali, Mrinal M. Patnaik, William J. Hogan, Kebede Begna, Michelle A Elliott, Nandita Khera, Jeanne M. Palmer, Naseema Gangat, Attilio Orazi, Katalin Kelemen, Kaaren K. Reichard, Dong Chen

Blood (2022) 140 (Supplement 1): 6872–6873.

https://doi.org/10.1182/blood-2022-167720

Published: 2022

Journal Articles

A Comparison of Financial Hardship Among Survivors of Childhood Cancer Treated with and without Hematopoietic Cell Transplantation: A Report from the Childhood Cancer Survivor Study

David K. Buchbinder, Neel S. Bhatt, Huiqi Wang, Yutaka Yasui, Saro H. Armenian, Smita Bhatia, Eric J. Chow, I-Chan Huang, Anne C. Kirchhoff, Wendy Leisenring, K. Robin Yabroff, Gregory T. Armstrong, Paul Nathan, Nandita Khera

Blood (2022) 140 (Supplement 1): 10981–10982.

https://doi.org/10.1182/blood-2022-159132

Published: 2022

Journal Articles

Therapy-Related Myelodysplastic Syndromes with Isolated Del(5q): Comparative Analysis of Phenotype and Long-Term Survival

Farah Fleti, Amritpal Singh, Aref Al-Kali, James M. Foran, Michelle A Elliott, Kebede Begna, Talha Badar, Nandita Khera, Mithun V. Shah, Hassan B. Alkhateeb, Maymona Abdelmagid, Kaaren K. Reichard, Rhett P. Ketterling, Animesh Pardanani, Naseema Gangat, Ayalew Tefferi

Blood (2022) 140 (Supplement 1): 6940–6941.

https://doi.org/10.1182/blood-2022-163518

Published: 2022

Journal Articles

Trends in Use and Outcomes of Autologous and Allogeneic Hematopoietic Cell Transplantation in Racial/Ethnic Minorities

Nandita Khera, Theresa E. Hahn, Ruta Brazauskas, Benjamin Jacobs, Leslie E. Lehmann, Hashmi Shahrukh, William A. Wood, Sikander Ailawadhi, Wael Saber

Blood (2021) 138 (Supplement 1): 427.

https://doi.org/10.1182/blood-2021-146967

Published: 2021

Journal Articles

The Sustainability of Price Dynamics in Precision Hematology

Caleb J Scheckel, Aakash Desai, Chelsee Jensen, Jacob Orme, Nandita Khera, Joshua C. Pritchett, Amit Mahipal, Ronald Go

Blood (2021) 138 (Supplement 1): 114.

https://doi.org/10.1182/blood-2021-152715

Published: 2021

NARROW

Impact of Total Body Irradiation-Based Conditioning Regimens on Outcomes in Patients with Aggressive Mature T-Cell Lymphomas Undergoing Allogeneic Hematopoietic Cell Transplant

Response-Stratified Genetic Risk Model for Newly-Diagnosed Acute Myeloid Leukemia Treated with Venetoclax + Hypomethylating Agent

Predictors of Relapse and Post-Relapse Outcomes in Patients with Newly-Diagnosed Acute Myeloid Leukemia Treated with Venetoclax + Hypomethylating Agent

Revumenib Maintenance Therapy Following Revumenib-Induced Remission and Transplant

Trial in Progress: Patient-Reported Outcome Measures in the Prospective Observational Cohort Study of Patients at Risk for Chronic Graft-Versus-Host Disease in the United States (THRIVE)

Preliminary Safety Results of the Open-Label Phase of a 2-Part Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of an Investigational Microbiome Therapeutic, SER-155, in Adults Undergoing Hematopoietic Cell Transplantation

Impact of Investigational Microbiome Therapeutic SER-155 on Pathogen Domination: Initial Results from a Phase 1b Study in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT)

Survival and Prognosis Among 301 Patients with Newly-Diagnosed Acute Myeloid Leukemia Following Venetoclax Plus Hypomethylating Agent Therapy

Evaluation of Atrial Fibrillation Risk and Outcome after Allogeneic Transplantation Using an Artificial Intelligence ECG Algorithm and Echocardiographic Parameters in an MDS Cohort

Impact of Publicly Reported Center Specific Analysis on Patient Selection Practices for Hematopoietic Stem Cell Transplantation

TP53 Variant Allele Frequency and Therapy-Related Setting Independently Predict Survival in Myelodysplastic Syndromes with Del(5q)

Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation for Hodgkin and Non-Hodgkin Lymphoma: Secondary Analysis from Two Multi-Center Randomized Controlled Trials of Hematopoietic Cell Transplant Survivorship Interventions

IPSS-Molecular but Not Individual Mutations Predicts Outcomes of Patients with Myelodysplastic Syndrome (MDS) after Allogeneic Hematopoietic Cell Transplantation (Allo-HCT): A Mayo Clinic Cohort

Outcomes after Transplant in Relapsed/Refractory KMT2Ar (MLLr) and mNPM1 (NPM1c) leukemia Patients Achieving Remissions after Menin Inhibition: SNDX-5613 (revumenib) Ph1 Experience

A Phase 1b Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of an Investigational Microbiome Therapeutic, SER-155, in Adults Undergoing Hematopoietic Stem Cell Transplantation

Reappraisal of Mast Cell Leukemia Based on a Single Institution Review of 16 Cases: Role of Mast Cell Morphology in Determining Clinical Outcome

A Comparison of Financial Hardship Among Survivors of Childhood Cancer Treated with and without Hematopoietic Cell Transplantation: A Report from the Childhood Cancer Survivor Study

Therapy-Related Myelodysplastic Syndromes with Isolated Del(5q): Comparative Analysis of Phenotype and Long-Term Survival

Trends in Use and Outcomes of Autologous and Allogeneic Hematopoietic Cell Transplantation in Racial/Ethnic Minorities

The Sustainability of Price Dynamics in Precision Hematology

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only